Related Experiment Video
Updated: Jan 27, 2026

Identification of Host Pathways Targeted by Bacterial Effector Proteins using Yeast Toxicity and Suppressor Screens
Published on: October 25, 2019
Targeting the Hexosamine Biosynthetic Pathway Prevents Plasmodium Developmental Cycle and Disease Pathology in
Pollyanna Stephanie Gomes1, Scott Tanghe2, Julio Gallego-Delgado2
1Centro de Pesquisas em Tuberculose, Instituto de Microbiologia, Faculdade de Medicina, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil.
Abstract:
Cerebral malaria (CM) is a clinical syndrome involving irreversible and lethal signs of brain injury associated to infection by parasites of the genus Plasmodium. The pathogenesis of CM derives from infection-induced proinflammatory cytokines associated with cytoadherence of parasitized red blood cells to brain microvasculature. Glycoconjugates are very abundant in the surface of Plasmodium spp., and are critical mediators of parasite virulence in host-pathogen interactions. Herein, we show that 6-Diazo-5-oxo-L-norleucine (DON) therapeutically used for blocking hexosamine biosynthetic pathway leads to recovery in experimental murine cerebral malaria. DON-induced protection was associated with decreased parasitism, which severely reduced Plasmodium transmission to mosquitoes. These findings point to a potential use of DON in combination therapies against malaria.
Insights
6-Diazo-5-oxo-L-norleucine (DON) aids recovery in experimental cerebral malaria (CM) by reducing parasite levels. This therapeutic approach also significantly lowers malaria parasite transmission to mosquitoes.
Area of Science:
- Infectious diseases
- Parasitology
- Neuroscience
Background:
- Cerebral malaria (CM) is a severe clinical syndrome caused by Plasmodium parasites, leading to lethal brain injury.
- Pathogenesis involves infection-induced proinflammatory cytokines and cytoadherence of infected red blood cells in cerebral microvasculature.
- Parasitic glycoconjugates are crucial virulence factors in Plasmodium spp. host-pathogen interactions.
Purpose of the Study:
- To investigate the therapeutic potential of 6-Diazo-5-oxo-L-norleucine (DON) in experimental murine cerebral malaria.
- To evaluate the impact of DON on parasite levels and transmission.
Main Methods:
- Treatment of experimental murine cerebral malaria with 6-Diazo-5-oxo-L-norleucine (DON).
- Assessment of therapeutic recovery and reduction in parasite load.
- Evaluation of Plasmodium transmission to mosquitoes following DON treatment.
Main Results:
- DON administration led to recovery in experimental murine cerebral malaria.
- DON treatment was associated with decreased Plasmodium parasitism.
- Reduced parasitism significantly lowered malaria parasite transmission to mosquitoes.
Conclusions:
- 6-Diazo-5-oxo-L-norleucine (DON) demonstrates therapeutic efficacy in experimental cerebral malaria.
- DON treatment reduces parasite burden and subsequent transmission, suggesting a dual benefit.
- DON represents a potential candidate for combination therapies against malaria.
Related Concept Videos
Amino Acid Biosynthetic Pathways
C4 Pathway and CAM
C4 Pathway
The C4 pathway is used by plants such as...
Coronary Artery Disease IV: Preventive Measures
Lysogenic Cycle of Bacteriophages
Lytic Cycle of Bacteriophages
Retrovirus Life Cycles

